Invitae's Breast Cancer Tests Get New Medicare Reimbursement Code

Apr 19, 2016

|

NEW YORK (GenomeWeb) – Invitae announced today that its multi-gene tests for hereditary breast cancer-related disorders will now be reimbursed by the Centers for Medicare and Medicaid Services (CMS) under a new molecular diagnostics current procedure terminology (CPT) code.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Science

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

New Framework Suggested

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

Penguins With Roving Eyes

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Funding Lost

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

Featured White Papers

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Aug

27

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep

17

Featured Webinar

Trends in Clinical NGS QC Management: Expert Insights to Ensure Quality Results for Your Lab

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

Sep

18

Featured Webinar

Validation and Internal QC of Clinical NGS to Support an Accredited Diagnostic Workflow

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.

Main menu